Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism
Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism
The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC:NMLSF) has started recruiting participants for the first-ever clinical trial assessing the effects of psilocybin in adults diagnosed with Fragile X Syndrome (FXS), the leading genetic cause of autism spectrum disorder.
合同研究組織之間的夥伴關係 KGK Sciences Inc. 和 Nova Mentis 生命科學公司 （OTC: NMLSF）已開始招募參與者參加有史以來第一項臨牀試驗，該試驗評估了psilocybin對被診斷患有脆性X綜合徵（FXS）的成年人的影響，脆性X綜合徵是自閉症譜系障礙的主要遺傳原因。
Taking place at KGK's London facility in Ontario, Canada, the 28-day Phase 2a study will test the safety and efficacy of repetitive oral microdoses (1.5 milligrams) of Nova's synthetic psilocybin NM-1001 on the cognitive and behavioral symptoms commonly seen in people with FXS diagnosis.
這項爲期 28 天的 2a 期研究在加拿大安大略省的 KGK 倫敦工廠進行，將測試重複口服微劑量（1.5 毫克）Nova 的合成 psilocybin NM-1001 對於 FXS 診斷患者常見的認知和行爲症狀的安全性和有效性。
Changes in the 10 participants will be measured through diagnostic and therapeutic mRNA and serotonin biomarker technology together with machine-learning artificial intelligence, or AI.
10名參與者的變化將通過診斷和治療性mRNA和血清素生物標誌物技術以及機器學習、人工智能（AI）來測量。
See Also: Cannabinoids & Autism — A Baltimore Company Is On Track To Start Phase 2 Clinical Trial For New Treatment
另見：大麻素和自閉症 — 巴爾的摩的一家公司有望開始新療法的2期臨牀試驗
The study aims for an unusually tested health condition and, so far, is one of the sole take-home psilocybin trials to have received Health Canada's approval.
該研究的目標是針對一種經過異常測試的健康狀況，是迄今爲止唯一獲得加拿大衛生部批准的psilocybin帶回家的試驗之一。
KGK's CEO Najla Guthrie says this trial is expected to make "a significant impact" in FXS, a disorder that "truly affects the lives of many families and that has not yet been studied."
KGK 的首席執行官 娜傑拉·格思裏 說，這項試驗預計將對FXS產生 “重大影響”，這種疾病 “確實影響了許多家庭的生活，尚未得到研究”。
Dr. Marvin S. Hausman, scientific advisory board chairman of Nova, says the study builds on "very positive" preclinical results of psilocybin as a potential new treatment for symptoms associated with autism, "the fastest-growing developmental disability in the world."
博士 Marvin S. Hausman，Nova科學顧問委員會主席說，這項研究建立在psilocybin的 “非常積極” 的臨牀前結果基礎上，psilocybin是治療自閉症相關症狀的潛在新療法，自閉症是 “世界上增長最快的發育障礙”。
The companies anticipate dosing will begin in the second quarter of this year, with preliminary results following suit.
兩家公司預計，劑量將在今年第二季度開始，初步結果將緊隨其後。
Photo: Benzinga edit with photo by Susie Hedberg and C4289N on Shutterstock.
照片：Benzinga 在 Shutterstock 上使用 Susie Hedberg 的照片和 C4289N 進行編輯。
Benzinga's PCC 2023
Benzinga 的 PCC 2023
Missed our Psychedelics Capital Conference? Here's some EXCLUSIVE coverage from the event's second edition:
錯過了我們的迷幻資本會議？以下是該活動第二版的一些獨家報道：
-
Investing In The Unique Growth Market Of Psychedelics
-
EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps
-
Infrastructure Built For Healing: 'Consolidation And Legitimacy Are Crucial For Psychedelic Industry Growth'
-
Ketamine Therapy Leaders Share Bold Vision For Future At Benzinga's Psychedelics Capital Conference
-
In Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'
-
Making The World A Better Place, How Psychedelics Are Helping
-
投資迷幻藥的獨特增長市場
-
獨家：搖頭丸療法專家就即將獲得的批准和迷幻市場爭論不休
-
爲治療而建的基礎設施：“整合與合法性對於迷幻行業的增長至關重要”
-
氯胺酮療法領導者在本辛加的迷幻資本會議上分享了對未來的大膽願景
-
在重塑心理健康和下一代迷幻藥中，“訪問和臨牀數據是關鍵”
-
讓世界變得更美好，迷幻藥如何提供幫助
譯文內容由第三人軟體翻譯。